AMENDMENT

In the Specification:

Please delete the title from the parent application and replace with the new title -- METHODS OF USING LATENT TGFβ BINDING PROTEINS --.

B1 At page 2, line 5, after "30, 1994", please insert --, which issued as U.S. Patent No. 5,942,496 on August 24, 1999--.

B2 At page 2, line 6, after "18, 1994", please insert --, which issued as U.S. Patent No. 5,763,416 on June 09, 1998--.

At page 21, beginning at line 24 and extending through page 22, line 15, please delete the entire text beginning with "**FIG. 9.**" and extending through "40091 antiserum."

N.E 6/11/2 B3 At page 48, line 9, after the paragraph that ends with "manner.", please insert the following new paragraph --Accordingly, an LTBP protein or polypeptide may be provided to a repair tissue site or bone progenitor tissue site. A nucleic acid segment (DNA or RNA) that expresses an LTBP protein or polypeptide in cells of the tissue site may be provided, as may a nucleic acid segment in association with a structural biocompatible matrix (U.S. Patent No. 5,942,496 and U.S. Patent No. 5,763,416).--.

B4 At page 75, line 7, after "pLTBP-3fl" please insert -- , deposited November 24, 1997 with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20852 (now at 10801 University Boulevard, Manassas, VA 20110-2209), and given the ATCC Accession numbers ATCC 209496--.

NE At page 75, line 11, after "1995)", please delete "(FIG. 9)".

B5 At page 75, at blank line 12, please insert --Co-transfection of 293T cells with pLTBP-3fl and pTGF-β1 was followed by immunoprecipitation of LTBP-3 and TGF-β1 produced by

293T cells following transient transfection and radiolabeling. Aliquots (~10^6 incorporated CPM) of radiolabeled media were immunoprecipitated and separated using 4%-18% gradient SDS-PAGE and either reducing or nonreducing conditions as described (Yin et al., 1995). Cold standards were used to estimate molecular weights (200, 97.4, 69, 46, 30, 21.5 and 14.3 kDa; Rainbow mix, Amersham). The immunoprecipitation was followed by: 1, 293T cell medium proteins immunoprecipitated with 274 antibody (separated under reducing conditions) after co-transfection with pLTBP-3fl and pTGF-β1; 2, 293T cell medium proteins immunoprecipitated with 274 antibody (separated under nonreducing conditions) after co-transfection with pLTBP-3fl and pTGF-β1; 3, untransfected 293T cell medium proteins immunoprecipitated with 274 antibody (separated under reducing conditions); 4, 293T cell medium proteins immunoprecipitated with 274 antibody (separated under reducing conditions) after transfection with pLTBP-3fl; 5, 293T cell medium proteins immunoprecipitated with 40091 antibody (separated under reducing conditions) after transfection with pTGF-β1; 6, 293T cell medium proteins immunoprecipitated with 40091 antibody (separated under nonreducing conditions) after transfection with pTGF-β1; and Lane 7, 293T cell medium proteins immunoprecipitated with 40091 antibody (separated under reducing conditions) after co-transfection with pLTBP-3fl and pTGF-β1. The signal was weakest in lanes in which proteins were immunoprecipitated using the 40091 antibody, reflecting the weaker affinity of the 40091 antiserum.---.

At pages 92-118, please delete the entire sequence listing. Please re-number the following pages (claims and abstract) consecutively.

After page 127 (abstract), please insert the correct sequence listing pages submitted August 24, 1999 in the parent application (see accompanying Request at Box 13) and number these pages separately beginning with page 1.